Physician profile
William C Padula
NPI 1205949518
$359.81
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.74 · 2020: $88.98 · 2021: $209 · 2022: $34.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $91.01 | 2020-2021 | |
| Novo Nordisk INC | $71.53 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $37.26 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.55 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.91 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.59 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.72 | 2020 | |
| Acadia Pharmaceuticals INC | $15.99 | 2021 | |
| Forte Bio-Pharma LLC | $12.45 | 2021 | |
| Merck Sharp & Dohme LLC | $12.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Padula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.